BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed DSGN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:4d56a5c888c6e323ed67@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:DSGN P1/P2 readout (est.): A Multiple Ascending Dose Study of DT-21
 6P2 in Patients With Friedreich's Ataxia
DESCRIPTION:A Multiple Ascending Dose Study of DT-216P2 in Patients With Fr
 iedreich's Ataxia\nNCT06874010 | PHASE1/PHASE2 | RECRUITING | sponsor: Des
 ign Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nTicker DSGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT06874010\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06874010
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
